arrow
L

Luke Vale

university of london
H指数:77
被引数:2.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

PARTIAL: study protocol for a clinical and cost-effectiveness of complex PARTIAL vs radical nephrectomy for clinically localised renal cell carcinoma randomised trial

部分:关于临床局部肾细胞癌复杂部分性肾切除术与根治性肾切除术的临床和经济有效性的随机试验研究方案

2026-03-010
PRE
Clinical and cost-effectiveness of eculizumab withdrawal in atypical haemolytic uraemic syndrome: the SETS aHUS multi-centre, open-label, prospective and single-arm study

阿typical haemolytic uraemic syndrome中eculizumab停用的临床和经济效果:SETS aHUS多中心、开放标签、前瞻性和单臂研究

2026-02-010
PRE
Surgery versus conservative management for severe pectus excavatum (RESTORE): protocol for a multicentre, randomised, controlled superiority trial

手术治疗与保守管理治疗严重漏斗胸(RESTORE):一项多中心、随机、对照优效性试验方案

2025-12-230
OAAI
Tele-ophthalmology-enabled and artificial intelligence-ready referral pathway for community optometry referrals of retinal disease: HERMES cluster randomised trial with a diagnostic accuracy study

远程眼科支持、人工智能兼容的视网膜疾病社区验光配镜转诊路径:HERMES集群随机试验与诊断准确性研究

2025-12-010
PRE
Stopping eculizumab treatment safely in atypical HUS: a multicentre, open-label, prospective, single-arm trial of the safety and impact of eculizumab withdrawal

在非典型HUS中安全停用依库珠单抗治疗:一项关于依库珠单抗撤药的安全性和影响的多中心、开放标签、前瞻性、单臂试验

2025-10-010
OAAI
Methods used in early value assessments for nice: a scoping review

早期价值评估中使用的nice方法:一项范围综述

2025-09-080
OAAI
Eculizumab withdrawal and monitoring in atypical haemolytic uraemic syndrome (SETS aHUS): a multicentre, open label, prospective, single arm trial

艾库珠单抗停药及监测在非典型溶血尿毒症综合征(SETS aHUS)中的应用:一项多中心、开放标签、前瞻性、单臂试验

2025-08-070
OA
Corrigendum to “Feasibility and acceptability of Autism Adapted Safety Plans: an external pilot randomised controlled trial”

勘误表,针对“自闭症适应性安全计划的可行性与可接受性:一项外部试点随机对照试验”

2025-06-010
PRE
Polyp detection with colonoscopy assisted by the GI Genius artificial intelligence endoscopy module compared with standard colonoscopy in routine colonoscopy practice (COLO-DETECT): a multicentre, open-label, parallel-arm, pragmatic randomised controlled trial
2024-10-012
PRE